Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Ovid Therapeutics's OV-329?
OV-329 is a small molecule commercialized by Ovid Therapeutics, with a leading Phase I program in Seizures. According to Globaldata,...
Data Insights
OV-329 by Ovid Therapeutics for Seizures: Likelihood of Approval
OV-329 is under clinical development by Ovid Therapeutics and currently in Phase I for Seizures. According to GlobalData, Phase I...